Literature DB >> 24650588

Antidepressant-like effect of Canavalia brasiliensis (ConBr) lectin in mice: evidence for the involvement of the glutamatergic system.

Débora K Rieger1, Ana Paula Costa1, Josiane Budni1, Morgana Moretti1, Sabrina Giovana Rocha Barbosa1, Kyria S Nascimento2, Edson H Teixeira2, Benildo S Cavada2, Ana Lúcia S Rodrigues1, Rodrigo B Leal3.   

Abstract

Lectins recognize and reversibly bind to carbohydrates attached to proteins and lipids modulating a variety of signaling pathways. We previously showed that ConBr, a lectin from Canavalia brasiliensis seeds, produced an antidepressant-like effect in mice by modulating the monoaminergic neurotransmitter systems. Moreover, ConBr blocked hippocampal neurotoxicity induced by quinolinic acid in vivo and by glutamate in vitro, suggesting a neuroprotective activity of ConBr via glutamatergic system modulation. Therefore, the present study was undertaken to investigate the involvement of the N-methyl-D-aspartate (NMDA) receptor and the L-arginine-nitric oxide (NO) pathway in the antidepressant-like action displayed by ConBr in the forced swimming test (FST). With the aim of verifying the involvement of NMDA receptors in the antidepressant-like effect of ConBr (10 μg/site, i.c.v.), an intracerebroventricular (i.c.v.) pretreatment with either NMDA (0.1 pmol/site) or D-serine (30 μg/site) was carried out. The results show that both treatments blocked the effect of ConBr. Furthermore, the coadministration of subeffective doses of the NMDA receptor antagonist MK-801 (0.001 mg/kg, i.p.) or ketamine (0.1 mg/kg, i.p.; NMDA receptor antagonist) and ConBr (0.1 μg/site, i.c.v.) caused a synergistic reduction in immobility time. In order to verify the dependence of the L-arginine-NO-cGMP pathway, on the effect of ConBr in the FST, a pretreatment with the NO precursor, L-arginine (750 mg/kg, i.p.), or the PDE5 inhibitor, sildenafil (5 mg/kg, i.p.), was performed. Both drugs abolished the antidepressant-like action of ConBr. Finally, the administration of subeffective doses of the soluble guanylate cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ; 30 pmol/site, i.c.v.) and ConBr (0.1 μg/site, i.c.v.) produced a synergistic antidepressant-like effect in the FST. Taken together, the results suggest that the antidepressant-like effect of ConBr in the FST involves NMDA receptor inhibition and reduction in NO and cGMP synthesis.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ConBr; Depression; Forced swimming test; Lectin; NMDA; Nitric oxide

Mesh:

Substances:

Year:  2014        PMID: 24650588     DOI: 10.1016/j.pbb.2014.03.008

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  4 in total

1.  ConBr, A Lectin Purified from the Seeds of Canavalia brasiliensis, Protects Against Ischemia in Organotypic Culture of Rat Hippocampus: Potential Implication of Voltage-Gated Calcium Channels.

Authors:  D K Rieger; E Navarro; I Buendia; E Parada; L González-Lafuente; R Leon; A P Costa; I A Heinrich; K S Nascimento; B S Cavada; M G Lopez; J Egea; R B Leal
Journal:  Neurochem Res       Date:  2016-10-17       Impact factor: 3.996

2.  Neuronal activity regulated pentraxin (narp) and GluA4 subunit of AMPA receptor may be targets for fluoxetine modulation.

Authors:  Isabella A Heinrich; Andiara E Freitas; Ingrid A V Wolin; Ana Paula M Nascimento; Roger Walz; Ana Lúcia S Rodrigues; Rodrigo B Leal
Journal:  Metab Brain Dis       Date:  2021-02-02       Impact factor: 3.584

Review 3.  A systematic review of studies investigating the acute effects of N-methyl-D-aspartate receptor antagonists on behavioural despair in normal animals suggests poor predictive validity.

Authors:  Martin Viktorov; Matthew P Wilkinson; Victoria C E Elston; Medi Stone; Emma S J Robinson
Journal:  Brain Neurosci Adv       Date:  2022-03-12

4.  Animal Galectins and Plant Lectins as Tools for Studies in Neurosciences.

Authors:  João Ronielly Campêlo Araújo; Cauê Barbosa Coelho; Adriana Rolim Campos; Renato de Azevedo Moreira; Ana Cristina de Oliveira Monteiro-Moreira
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.